Open Access

The neurotransmitter dopamine modulates vascular permeability in the endothelium

Journal of Molecular Signaling20083:14

https://doi.org/10.1186/1750-2187-3-14

Received: 02 June 2008

Accepted: 28 July 2008

Published: 28 July 2008

Abstract

Background

Vascular permeability factor/Vascular endothelial growth factor (VPF/VEGF), a multifunctional cytokine, is a potent inducer of vascular permeability, an important early step in angiogenesis. It is known that the neurotransmitter dopamine can inhibit VPF/VEGF mediated angiogenesis, in particular microvascular permeability, but the effectors of this action remain unclear.

Results

Here, we define the signaling pathway modulated by dopamine that inhibits VPF/VEGF induced vascular permeability in endothelial cells. Signals from VPF/VEGF lead to changes in the phosphorylation of tight junction protein zonula occludens (ZO-1) and adherens junction proteins like VE-cadherin and associated catenins, thus weakening endothelial cell-cell adhesion and increasing vascular permeability. We found VEGF receptor-2 (VEGFR-2) to be part of a multi-protein complex involving ZO-1, VE-cadherin and β-catenin. VPF/VEGF induced phosphorylations of VE-cadherin, β-catenin and ZO-1 were inhibited by dopamine treatment. Association of occludin with ZO-1 and ZO-1 with VE-cadherin were significantly inhibited by dopamine in VEGF treated cells. Furthermore, we identified Src as an important target for dopamine-mediated inhibition of VPF/VEGF induced permeability.

Conclusion

Taken together, our results provide molecular insights of dopamine function in the vascular endothelium and suggest a central role of Src in regulating key molecules that control vascular permeability.

Background

Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) is a multifunctional cytokine that plays a critical role in angiogenesis [13]. It is a pleiotropic growth factor that mediates multiple functions via stimulation of its cognate receptors on endothelial cells [13]. VPF/VEGF was originally described as a tumor-secreted protein that renders venules and small veins hyperpermeable to circulating macromolecules and was, therefore, initially termed vascular permeability factor [15]. In fact, VPF/VEGF is one of the most potent inducers of vascular permeability known. It is 50,000-fold more potent than histamine [1, 36]. This ability to enhance microvascular permeability remains one of the most important properties of VPF/VEGF, especially with regard to the hyperpermeability of tumor vessels that is attributable to tumor cell expression of VPF/VEGF [1, 36]. Furthermore, it has been suggested that the increase in permeability results in the leakage of several plasma proteins, including fibrinogen and other clotting proteins. This can lead to the deposition of fibrin in the extravascular space, which subsequently retards the clearance of edema fluid and transforms the normally antiangiogenic stroma of normal tissues into a proangiogenic environment [1, 35]. VPF/VEGF increases permeability in a variety of vascular beds – including those of the skin, peritoneal wall, mesentery, and diaphragm – and can lead to pathologic conditions such as malignant ascites [3, 7] and malignant pleural effusions [3, 8]. In fact, there is evidence that inhibition of VPF/VEGF can lead to decreased formation of pleural effusions [3, 8] and that antibodies directed against VPF/VEGF or VEGFR-2 can lead to a decrease in tumor vessel permeability and ascites formation [1, 3, 810].

Vascular permeability, as induced by VPF/VEGF, is due to its action on the endothelium. Endothelial cell-to-cell junctions are complex structures formed by different adhesive molecules [11, 12]. Endothelial cells have tight junctions (TJ) and adherens junctions (AJ). AJ are formed by transmembrane proteins that belong to the cadherin superfamily such as vascular endothelial VE-cadherin [11, 13]. These proteins are linked inside the cells to β-catenin and plakoglobin that in turn, through the binding to α-catenin, promote anchorage to the actin cytoskeleton and are required for full control of junctional permeability [14]. TJ, in contrast, are formed by three different types of transmembrane proteins: occludin [15], claudins [16], and junctional adhesion molecule (JAM) [17]. Inside the cells, several cytoskeletal signaling molecules are concentrated in the TJ area, such as ZO-1, cingulin, and 7H6 [18, 19].

We have recently demonstrated that dopamine significantly and specifically inhibits VPF/VEGF induced vascular permeability in the endothelial cells in vivo [2023]. However, the effectors by which dopamine mediates this action is unclear [2023]. VPF/VEGF induced increase in vascular permeability is either through disruption or change in localization of ZO-1 and VE-cadherin between the endothelial cells [6, 2427]. Reports also show that quiescent blood vessels contain a complex involving VEGFR-2, VE-cadherin and β-catenin that are transiently disrupted by VPF/VEGF injection. Blockade of Src prevents disassociation of this complex and inhibits edema accumulation [28, 29]. Accordingly, we investigated whether dopamine mediated inhibition of VPF/VEGF induced vascular permeability is a result of its antagonism of VPF/VEGF induced disruption of VEGFR-2, ZO-1, β-catenin and VE-cadherin complex in the endothelial cells. We also investigated if dopamine mediated modulation of TJ and AJ proteins in the vascular endothelium in response to VPF/VEGF were Src dependent.

Results

Dopamine inhibits VPF/VEGF mediated in vitro permeability

VPF/VEGF induced permeability significantly increased in cultured HUVEC compared to the untreated cells. However, permeability significantly decreased when HUVEC were pre-treated with 10 uM dopamine or the specific dopamine D2 receptor agonist quinpirole before administering VPF/VEGF (Figure 1). These results are consistent with our previous in vivo findings where we demonstrated that dopamine significantly and specifically inhibited VPF/VEGF induced vascular permeability in the endothelial cells [2023]. Here we have focused on the possible mechanism by which dopamine mediates this inhibition.
Figure 1

Dopamine inhibits VEGF induced in vitro permeability in HUVEC. Permeability is represented by relative fluorescence units as measured by a flux of FITC-Dextran across monolayer of HUVEC cultures in collagen-coated transwells. In the figure C-V is the control, HUVEC without any VPF/VEGF or dopamine treatment, C+V is the HUVEC treated with only VPF/VEGF (10 ng/ml) for 90 min, D+V is the HUVEC pre-treated with 10 μM dopamine for 15 min and then treated with VPF/VEGF (10 ng/ml) for 90 min and Q+V is the HUVEC pretreated with 10 μM quinpirole for 15 min and then treated with VPF/VEGF (10 ng/ml) for 90 min. Experiments were repeated three times in triplicate.

Dopamine modulates association of VEGFR-2 with Src

We demonstrated by immunoprecipitation in HUVEC that Src remained constitutively associated with VEGFR-2, and this association increased with VPF/VEGF treatment. However pre-treatment with dopamine significantly inhibited this association (Figure 2).
Figure 2

Dopamine treatment alters VEGF/VPF induced VEGR-2 and c-Src association in HUVEC. HUVEC extracts were immunoprecipitated with VEGFR-2 antibody and immunoblotted with Src and VEGFR-2 antibody. In the figure C-V is the control, HUVEC without any VPF/VEGF or dopamine treatment, C+V is the HUVEC treated with only VPF/VEGF (10 ng/ml) for 15 min, D-V is the HUVEC treated with 10 μM dopamine for 15 min and D+V is the HUVEC pretreated with 10 μM dopamine for 15 min and then treated with VPF/VEGF (10 ng/ml) for 15 min. Q-V is the HUVEC treated with 10 μM quinpirole for 15 min and Q+V is the HUVEC pretreated with 10 μM quinpirole for 15 min and then treated with VPF/VEGF (10 ng/ml) for 15 min. The figures are representative of three separate experiments with similar results.

Activation of Src is dependent on tyrosine phosphorylation of VEGFR-2

Next we wanted to determine if activation of Src was dependent on phosphorylation of VEGFR-2. At first we confirmed efficacy of the kinase inhibitor (KINASE IV) by treating HUVEC with the inhibitor with or without VPF/VEGF and determined that phosphorylation of Y1175 on VEGFR-2 was significantly decreased (Figure 3A), subsequently total tyrosine phosphorylation of VEGFR-2 was also decreased (data not shown). Next HUVEC were pre-treated with dopamine or kinase inhibitor with or without VPF/VEGF. A basal level of phosphorylation at Y418 of Src was observed in control cells. This was significantly enhanced upon stimulation with VPF/VEGF. However, pre-treatment with either dopamine or kinase inhibitor caused a significant decrease in Y418 phosphorylation and, therefore, activation [30] of Src (Figure 3B). Hence, from our data thus far we infer that dopamine by decreasing tyrosine phosphorylation on VEGFR-2 inhibited the association of Src with VEGFR-2 resulting in inhibition of Src activation.
Figure 3

VPF/VEGF induced VEGFR-2 phosphorylation is required for Src phosphorylation. (A) Kinase inhibitor (250 nM) inhibits VPF/VEGF induced VEGFR-2 Y1175 phosphorylatin. In the figure C-V is control, HUVEC without any VPF/VEGF or dopamine treatment, C+V is the HUVEC treated with only VEGF (10 ng/ml) for 15 min, C+KI+V is the HUVEC pretreated with kinase inhibitor (KINASE IV) for 30 min and treated with VPF/VEGF (10 ng/ml) for another 15 min (B) Pre-treatment of HUVEC with kinase inhibitor inhibits VEGF induced Src Y418 phosphorylation. In the figure C-V is control, HUVEC without any VPF/VEGF or dopamine treatment, C+V is the HUVEC treated with only VPF/VEGF (10 ng/ml) for 15 min, C+KI+V is the HUVEC pre-treated with kinase inhibitor for 30 min and treated with VPF/VEGF (10 ng/ml) for another 15 min and D+V is the HUVEC pretreated with 10 μM dopamine for 15 min and then treated with VPF/VEGF (10 ng/ml) for 15 min. The figures are representative of three separate experiments with similar results.

VPF/VEGF mediated disruption of ZO-1 between the endothelial cells is abrogated by dopamine

Among the tight junctions, ZO-1 plays an important role in maintaining vascular permeability [6, 25]. Moreover, recent reports also indicate that the VPF/VEGF induced vascular leak is through the disruption and phosphorylation of ZO-1 between the endothelial cells [6, 2427, 31]. We therefore determined whether the action of dopamine is through suppression of VPF/VEGF mediated disruption of ZO-1 in HUVEC. Our confocal microscopy experiments demonstrated that although treatment with VPF/VEGF disrupted ZO-1 between HUVEC in comparison to the untreated controls (Figure 4A and 4B), pre-treatment with either dopamine or quinpirole significantly abolished this effect of VPF/VEGF (Figure 4C and 4D). Neither dopamine nor quinpirole had any direct effects on the integrity of ZO-1 between the endothelial cells (data not shown), thereby confirming that the action of dopamine was VPF/VEGF specific and it was through dopamine D2 receptors.
Figure 4

Confocal microscopy images of tight junctions in HUVEC. (A) normal ZO-1 in untreated control HUVEC (B) disrupted ZO-1 in VPF/VEGF (10 ng/ml) treated HUVEC (C) dopamine (10 μM) + VPF/VEGF (10 ng/ml) treated HUVEC shows that pre-treatment with dopamine inhibits the ZO-1 disrupting property of VPF/VEGF (D) quinpirole (10 μM) + VPF/VEGF (10 ng/ml) treated HUVEC shows that pre-treatment with quinpirole inhibits the ZO-1 disrupting property of VPF/VEGF. The figures are representative of three separate experiments with similar results. Average intensity of ZO-1 staining for each cell was measured using metamorph software (version 7, Molecular Devices Inc., Toronto, Canada). Scale bar, 20 μm.

VPF/VEGF induced association between tight junction proteins, ZO-1 and occludin, are inhibited by dopamine

Occludin is an integral membrane protein closely associated with the tight junctions of epithelial and endothelial cells. ZO-1 has been demonstrated to interact with the transmembrane protein occludin, and it has a role in the localization of occludin to tight junctions [32]. Lysates from serum starved HUVEC were immunoprecipitated with ZO-1 antibody and immunoblotted with antibody against occludin. ZO-1 and occludin were constitutively associated with each other. The association between ZO-1 and occludin increased significantly upon treatment with VPF/VEGF (10 ng/ml), and this association was inhibited by dopamine (10 μM) pre-treatment (Figure 5). Our data clearly suggest that dopamine inhibits VPF/VEGF induced association of ZO-1 with occludin and might explain the inhibitory effect of dopamine in VPF/VEGF induced permeability.
Figure 5

Effect of dopamine on ZO-1 and occludin association. Immunoprecipitation experiment showed ZO-1 and occludin were constitutively associated with each other. In the figure C-V is the control, HUVEC without any VPF/VEGF or dopamine treatment, C+V is the HUVEC treated with only VPF/VEGF (10 ng/ml) for 5 min, D-V is the HUVEC treated with 10 μM dopamine for 15 min and D+V is the HUVEC pretreated with 10 μM dopamine for 15 min and then treated with VPF/VEGF (10 ng/ml) for 5 min. The figures are representative of three separate experiments with similar results.

Recent reports indicate that VPF/VEGF induced disruption of ZO-1 in the endothelial cells is associated with increased phosphorylation of ZO-1 in these cells [6, 24]. We thus investigated whether treatment with dopamine has any effect on VPF/VEGF induced increase in ZO-1 phosphorylation in HUVEC. VPF/VEGF treatment significantly increased ZO-1 phosphorylation in HUVEC in comparison to untreated controls (Figure 6A). However, cells pretreated with dopamine significantly inhibited VPF/VEGF induced ZO-1 phosphorylation. A similar effect was demonstrated with quinpirole (data not shown). Our data suggest that the action of dopamine was through dopamine D2 receptors, and we next questioned if this observation could be mimicked in vivo.
Figure 6

Effect of dopamine on VPF/VEGF-induced phosphorylation of ZO-1 in vitro and in vivo. (A) Decreased VPF/VEGF-induced phosphorylation of ZO-1 in HUVEC incubated with dopamine (10 μM) for 15 min before VPF/VEGF (10 ng/ml) treatment. In the figure C-V is control, HUVEC without any VPF/VEGF or dopamine treatment, C+V is the HUVEC treated with only VPF/VEGF (10 ng/ml) for 5 min, D-V is the HUVEC treated with 10 μM dopamine for 15 min and D+V is the HUVEC pretreated with 10 μM dopamine for 15 min and then treated with VPF/VEGF (10 ng/ml) for 5 min. The figures are representative of three separate experiments with similar results. (B) Increased VPF/VEGF-induced phosphorylation of ZO-1 in mesenteric vascular endothelium (MVE) of mice treated with 500 ng of VPF/VEGF [C+V] and decreased VPF/VEGF-induced phosphorylation of ZO-1 in MVE of mice treated with either quinpirole (10 mg/kg i.p.) [Q+V] or dopamine (50 mg/kg i.p.) [D+V] 10 min before VPF/VEGF (500 ng) treatment were detected. C-V is the untreated control.

It was observed that administration of either dopamine or quinpirole into mice prior to VPF/VEGF treatment significantly inhibited ZO-1 phosphorylation (Figure 6B) in the mesenteric vascular endothelium of these animals, thereby validating our in vitro results in vivo. Overall, our data clearly suggest that VPF/VEGF induced hyperpermeability is controlled by dopamine through its D2R pathways, and it is mainly by controlling posttranslational modification of tight junction proteins.

Dopamine modulates association between AJ and TJ proteins

VE-cadherin is specifically localized to the inter-endothelial cell junction [13]. VE-cadherin inside the cell is linked to β-catenin that in turn promotes anchorage to the cytoskeleton. Adherens junction, in particular VE-cadherin, is a target of the signaling pathway that increases vascular permeability through VPF/VEGF [13, 3335]. In addition to influencing the tight junction proteins, signals from growth factors such as VPF/VEGF lead to changes in the phosphorylation of adherens junction proteins like VE-cadherin and associated catenins, thus weakening endothelial cell-cell adhesion and increasing vascular permeability. In order to determine the role of dopamine, if any, in affecting this complex, serum starved HUVEC were pre-treated with or without dopamine before adding VPF/VEGF (10 ng/ml). Then cell lysates were immunoprecipitated with VE-cadherin antibody. Interestingly, we observed that VEGFR-2, ZO-1, and β-catenin were constitutively associated with VE-cadherin (Figure 7). Treatment with VPF/VEGF significantly increased the association between VE-cadherin and ZO-1; however, pre-treatment with dopamine decreased the association (Figure 7). On the other hand, neither VPF/VEGF nor dopamine treatment induced any significant changes in the association between VE-cadherin and β-catenin or VEGFR-2.
Figure 7

ZO-1, β-catenin, VE-Cadherin and VEGFR-2 are in the same immunocomplex. Immunoprecipitation with VE-cadherin antibody showed constitutive association between VE-cadherin, VEGFR-2, β-catenin and ZO-1. In the figure C-V is control, HUVEC without any VPF/VEGF or dopamine treatment, C+V is the HUVEC treated with only VPF/VEGF (10 ng/ml) for 5 min, D-V is the HUVEC treated with 10 μM dopamine for 15 min and D+V is the HUVEC pretreated with 10 μM dopamine for 15 min and then treated with VPF/VEGF (10 ng/ml) for 5 min. The figures are representative of three separate experiments with similar results.

We then investigated whether treatment with dopamine has any effect on VPF/VEGF induced increase in VE-cadherin and β-catenin phosphorylation in vascular endothelium. VPF/VEGF treatment significantly increased VE-cadherin and β-catenin phosphorylation in HUVEC as compared to the untreated controls (Figure 8A and 8B). Even so, dopamine pre-treatment completely inhibited VE-cadherin and β-catenin phosphorylation in VPF/VEGF treated cells. (Figure 8A and 8B).
Figure 8

Dopamine pre-treatment inhibits VPF/VEGF-induced phosphorylation of β-catenin and VE-cadherin. HUVEC were pretreated with dopamine (10 μM) 15 min before VPF/VEGF (10 ng/ml) treatment. In the figure C-V is control, HUVEC without any VPF/VEGF or dopamine treatment, C+V is the HUVEC treated with only VPF/VEGF (10 ng/ml) for 5 min and D+V is the HUVEC pretreated with 10 μM dopamine for 15 min and then treated with VPF/VEGF (10 ng/ml) for 30 min. The cell extracts were immunoprecipitated (IP) with anti-phosphotyrosine antibodies and immunoblotted (IB) with either (A) anti-β-catenin or (B) anti-VE-cadherin antibodies. The figures are representative of four separate experiments with similar results.

Discussion

Here we demonstrate that the neurotransmitter dopamine is a potent regulator of the important signaling cascades controlling VPF/VEGF mediated vascular permeability [3, 6], an essential early step in angiogenesis [1, 3]. These results provide new mechanistic insights into the dopamine-mediated inhibition of the activities of VPF/VEGF. Src by regulating phosphorylation of key junctional proteins such as VE-cadherin, b-catenin and occludin regulates endothelial permeability (11, 35). Furthermore ZO-1 dissociates from occludin upon phosphorylation by Src (11, 35). Src knockout mouse or otherwise blockade of Src inhibits edema accumulation and thus permeability [28, 29]. Here we showed that dopamine inhibited VEGF induced association and activation of Src with VEGFR-2. We also showed that Src Y418 phosphorylation and hence its activation was dependent upon tyrosine phosphorylation of VEGFR-2. Dopamine also inhibited the interaction between TJ proteins and phosphorylation of proteins involved in formation of the AJ complex in endothelial cells. Association of occludin with ZO-1 and ZO-1 with VE-cadherin was significantly inhibited by dopamine in VEGF treated cells. VPF/VEGF induced phosphorylations of VE-cadherin, β-catenin and ZO-1 were also inhibited by dopamine treatment. Various studies have reported that phosphorylation of VE-cadherin or β-catenin correlate with increased endothelial permeability [11, 34]. Therefore, we infer that dopamine by decreasing tyrosine phosphorylation of VEGFR-2 inhibits association of Src with VEGFR-2 resulting in inhibition of Src activation. This reduced Src activation then results in decreased phosphorylation of ZO-1, VE-cadherin and β-catenin leading to stabilization of junctional complexes and restoration of endothelial barrier function.

Our in vitro results were corroborated by our experiment in vivo in that VPF/VEGF induced tyrosine phosphorylation of ZO-1 was significantly inhibited by pre-treatment with dopamine or quinpirole. These results justify our previous report where we showed that mice deficient in peripheral dopamine had increased microvascular permeability following VPF/VEGF administration [21, 23]. Our results are in accordance with a recent report that states that hypothermia induced loss of endothelial barrier function can be restored by dopamine pre-treatment [36]. The effect of dopamine thus far is selective for VPF/VEGF, as dopamine does not affect vascular permeability enhancing action of bradykinin or platelet-activating factor [20].

Furthermore endothelial cells expressed D1, D2 and D5 dopamine receptors as determined by western blot and RT-PCR (data not shown); however, the permeability inhibiting functions were mediated mostly by the dopamine D2 receptors. In a previous report we had shown that the D1 agonist SKF38393 or two other catecholamine vasopressors, epinephrine and norepinephrine, which do not interact with D2 receptors, did not alter or affect tumor ascites [20].

Finally, our result is significant because recent clinical efforts are underway to pharmacologically block VPF/VEGF mediated leakage in patients after acute myocardial infarction [6]. This therapeutic effort in turn may have a major impact on reducing tissue injury and thereby minimize the long-term consequences in this group of patients [6]. A similar approach may become available for stroke patients or individuals with retinal edema, where VPF/VEGF induced enhanced vascular permeability plays an important pathogenic role [6]. Blocking VPF/VEGF mediated vascular leakage can also have a critical effect in cancer patients by reducing metastatic entry of tumor cells into or out of the vascular circulation [1, 3, 6]. Most importantly, dopamine has been used in the clinics for several years in the treatment of cardiogenic shock complicating myocardial infarction [37]. Taken together, our study suggests a novel and a new therapeutic role for dopamine in these patients. In addition, this report also identifies the molecular mechanism of dopamine's influence on VPF/VEGF induced permeability.

Conclusion

The main conclusions are: 1. We found VEGFR-2 to be part of a multi-protein complex involving ZO-1, VE-cadherin and β-catenin. 2. VPF/VEGF induced phosphorylations of VE-cadherin, β-catenin and ZO-1 were inhibited by dopamine treatment. 3. Association of occludin with ZO-1 and ZO-1 with VE-cadherin were significantly inhibited by dopamine in VEGF treated cells. 4. Furthermore dopamine inhibited VPF/VEGF induced activation and association of Src with VEGFR-2.

Methods

Reagents

ZO-1 antibody (sc-10804), VE-cadherin antibody (sc-6458), β-catenin antibody (sc-7963), Occludin antibody (sc-8144), Src antibody (sc-5266) and VEGFR-2 (sc-504) antibody were from Santa Cruz Biotechnology, California, USA. Anti-phosphotyrosine monoclonal antibody (4G10) and phospho-Src [pTyr418] antibody were from Biosource International, Inc., CA; and AlexaFlour 546 secondary antibody was from Molecular Probes, OR. Aclar® fluoropolymer film was from Honeywell, NJ. Dopamine hydrochloride for in vitro, quinpirole and all other chemicals if not mentioned were from Sigma-Aldrich, MO. Dopamine hydrochloride for in vivo use was from Abbott Laboratories, IL. VPF/VEGF was from R &D Systems, MN. VEGF receptor 2 Kinase inhibitor IV was from Calbiochem (Cat # 676489).

Animals

Five- to six-week-old NIHBNX-MMC mice were purchased from the Taconic Farms, Germantown, NY. The animals were caged in plastic tubs covered with stainless steel tops at a temperature between 23 and 25°C, humidity level of 50 ± 10%, and a 12:12-h light-dark cycle. The mice were given ad libitum water and food.

Immunofluorescence

2 × 103 HUVEC were seeded on collagen coated Lab-Tek chamber slides. After four days of culture when these cells were confluent, they were serum starved for 24 hours. Thereafter, these cells were treated with either dopamine (10 μM) or a specific dopamine D2 receptor agonist quinpirole (10 μM) [20], followed 10 min later by addition of 20 ng of VPF/VEGF for 1 h. Thereafter, the cells were washed with PBS and fixed in 4% paraformaldehyde (PFA). Slides were again re-washed with PBS, blocked in 10% goat serum, and stained with anti-ZO-1 antibody (1:100 dilution, except phosphotyrosine antibodies were used at 1:1000) in 1% goat serum for 2 h. Finally, the slides were washed in PBS and incubated 1 hr in AlexaFlour 546 secondary antibody at a dilution of 1:200 followed by postfixing in 4% PFA and mounted in Vectashield (Vector Labs). Confocal microscopy was performed using a Zeiss LSM 510 confocal laser scan microscope with C-Apochromat 63x/NA1.2 water-immersion lense. Absence of signal crossover was established using single-labeled samples [20, 38].

Immunoprecipitation and Western blot analysis in vitro

HUVEC lysates in NP-40 buffer supplemented with protease inhibitor cocktail were immunoprecipitated with different antibodies (1:100 dilutions) and immunocomplexes were captured on protein A-agarose beads. Thereafter, samples were subjected to SDS-PAGE and then transferred to polyvinyl difluoride membranes and immunoblotted. Antibody-reactive bands were finally detected by enzyme-linked chemiluminescence (Amersham) and quantified by laser densitometry [2023].

In vitro permeability assay

The assay was performed according to established manufacturer's protocol, Catalog# ECM 640, Chemicon International Inc., CA. Briefly, 2 × 105 HUVEC in 200 μL were seeded onto collagen coated inserts in 24 well plates. 700 μL complete EBM medium was added to the plates. The cells were allowed to grow for 4–5 days until a monolayer was formed. The medium was replaced with phenol free starving EBM medium containing 0.1% FBS for 12–14 hrs. The respective inserts containing HUVEC were then pre-treated with 10 μM Dopamine or Quinpirole for 15 min. Subsequently, FITC-Dextran containing medium (phenol free EBM) with or without VEGF at 10 ng/ml was added. Fluorescence was measured after 90 min on the Spectra Flour Plus using excitation and emission wavelengths of 485 nm/535 nm.

Collection of Mesentery from Mice and Immunoprecipitation, Immunoblotting of the mesenteric homogenates

Animal protocols were approved by the Mayo Clinic Institutional Animal Care and Use Committee. Mesenteries were collected from normal 5–6 week-old NIHBNX-MMC mice and treated either with the anti-angiogenic dose of dopamine (50 mg/kg i.p) or specific dopamine D2 receptor agonist quinpirole (10 mg/kg ip) 10 min before VPF/VEGF injection. Briefly, normal mice previously treated with either dopamine or D2 receptor agonist was injected i.p. with 500 ng of recombinant human VPF/VEGF in 1 ml of HBSS. After 1 h, these animals were anesthetized with an injection of 0.4–0.75 mg/g ip Avertin and were euthanized by decapitation. The abdomen was then opened, loops of the small intestine were exteriorized, and mesentery windows including fatty vascular portions were dissected free and transferred to HBSS at 4°C. Four to six mesenteric windows, each roughly 1–3 cm2 in area, could be isolated from a single mouse.

Thereafter, mesenteries were homogenized immediately upon collection with a polytron tissue homogenizer (model PCU II; Kinematica AG, Switzerland) in a precipitation assay buffer [50 mM Tris (pH 7. 5), 0.25% sodium deoxycholate, 1% NP40, 150 mM NaCl, 1 ml Na3 VO4, 2 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 10 ug/ml leupeptin, 0.5% aprotinin, and 2 mM pepstatin A for 10 s at 4°C. Homogenates were then centrifuged for 5 min at 4°C, and supernatants were immunoprecipitated with different antibodies (1:100 dilution), and immunocomplexes was captured on protein A-agarose beads. Finally, samples were subjected to SDS-PAGE and then transferred to polyvinyl difluoride membranes and immunoblotted. Antibody-reactive bands was detected by enzyme-linked chemiluminescence (Amersham) and quantified by laser densitometry [32]. Since these animals were severely immunocompromised (T, NK and B cell deficient), the chance of any immune reaction mediated changes in the vascular permeability (which includes edema) following exogenous VPF/VEGF treatment was negligible.

Statistics

Differences among groups were evaluated by ANOVA and the unpaired Student's t-test or Dunn's multiple-comparison test. Statistical significance was assigned when P < 0.05 [2023]. Error bars were given on the basis of standard deviation (SD) values.

Abbreviations

VPF: 

Vascular permeability factor

VEGF: 

Vascular endothelial growth factor

VEGFR-2: 

Vascular endothelial growth factor receptor-2

HUVEC: 

Human umbilical vein endothelial cells

DA: 

Dopamine

D2DR: 

Dopamine D2 receptor

VE-cadherin: 

Vascular endothelial cadherin

ZO-1: 

Zonula occludens 1

TJ: 

Tight junctions

AJ: 

Adherens junctions.

Declarations

Acknowledgements

We would like to thank Jim Tarara for help with the confocal microscopy experiments and Dr. S. Basu for discussions. This work is partly supported by NIH grants CA78383, HL072178 and HL70567 and also a grant from American Cancer Society to DM.

Authors’ Affiliations

(1)
Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine
(2)
Department of Pathology, Massachusetts General Hospital

References

  1. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20:4368–4380.View ArticlePubMedGoogle Scholar
  2. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002, 2:795–803.View ArticlePubMedGoogle Scholar
  3. Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011–1027.View ArticlePubMedGoogle Scholar
  4. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983–985.View ArticlePubMedGoogle Scholar
  5. Senger DR, Perruzzi CA, Feder J, Dvorak HF: A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986, 46:5629–5632.PubMedGoogle Scholar
  6. Weis SM, Cheresh DA: Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005, 437:497–504.View ArticlePubMedGoogle Scholar
  7. Yoshiji H, Kuriyama S, Hicklin DJ, Huber J, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H: The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology 2001, 33:841–847.View ArticlePubMedGoogle Scholar
  8. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996, 93:14765–14770.View ArticlePubMedGoogle Scholar
  9. Ferrara N, Kerbel RS: Angiogenesis as a therapeutic target. Nature 2005, 438:967–974.View ArticlePubMedGoogle Scholar
  10. Jain RK, Duda DG, Clark JW, Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006, 3:24–40.View ArticlePubMedGoogle Scholar
  11. Dejana E: Endothelial adherens junctions: implications in the control of vascular permeability and angiogenesis. J Clin Invest 1996, 98:1949–1953.View ArticlePubMedGoogle Scholar
  12. Lampugnani MG, Dejana E: Interendothelial junctions: structure, signalling and functional roles. Curr Opin Cell Biol 1997, 9:674–682.View ArticlePubMedGoogle Scholar
  13. Lampugnani MG, Resnati M, Raiteri M, Pigott R, Pisacane A, Houen G, Ruco LP, Dejana E: A novel endothelial-specific membrane protein is a marker of cell-cell contacts. J Cell Biol 1992, 118:1511–1522.View ArticlePubMedGoogle Scholar
  14. Navarro P, Caveda L, Breviario F, Mandoteanu I, Lampugnani MG, Dejana E: Catenin-dependent and -independent functions of vascular endothelial cadherin. J Biol Chem 1995, 270:30965–30972.View ArticlePubMedGoogle Scholar
  15. Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S, Tsukita S: Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 1993, 123:1777–1788.View ArticlePubMedGoogle Scholar
  16. Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S: Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 1998, 141:1539–1550.View ArticlePubMedGoogle Scholar
  17. Martin-Padura I, Lostaglio S, Schneemann M, Williams L, Romano M, Fruscella P, Panzeri C, Stoppacciaro A, Ruco L, Villa A, et al.: Junctional adhesion molecule, a novel member of the immunoglobulin superfamily that distributes at intercellular junctions and modulates monocyte transmigration. J Cell Biol 1998, 142:117–127.View ArticlePubMedGoogle Scholar
  18. Anderson JM, Fanning AS, Lapierre L, Van Itallie CM: Zonula occludens (ZO)-1 and ZO-2: membrane-associated guanylate kinase homologues (MAGuKs) of the tight junction. Biochem Soc Trans 1995, 23:470–475.PubMedGoogle Scholar
  19. Gumbiner BM: Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996, 84:345–357.View ArticlePubMedGoogle Scholar
  20. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D: The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001, 7:569–574.View ArticlePubMedGoogle Scholar
  21. Basu S, Sarkar C, Chakroborty D, Nagy J, Mitra RB, Dasgupta PS, Mukhopadhyay D: Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis. Cancer Res 2004, 64:5551–5555.View ArticlePubMedGoogle Scholar
  22. Chakroborty D, Sarkar C, Mitra RB, Banerjee S, Dasgupta PS, Basu S: Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin Cancer Res 2004, 10:4349–4356.View ArticlePubMedGoogle Scholar
  23. Sarkar C, Chakroborty D, Mitra RB, Banerjee S, Dasgupta PS, Basu S: Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. Am J Physiol Heart Circ Physiol 2004, 287:H1554–1560.View ArticlePubMedGoogle Scholar
  24. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW: Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999, 274:23463–23467.View ArticlePubMedGoogle Scholar
  25. Dejana E, Corada M, Lampugnani MG: Endothelial cell-to-cell junctions. Faseb J 1995, 9:910–918.PubMedGoogle Scholar
  26. Harhaj NS, Antonetti DA: Regulation of tight junctions and loss of barrier function in pathophysiology. Int J Biochem Cell Biol 2004, 36:1206–1237.View ArticlePubMedGoogle Scholar
  27. Wang W, Dentler WL, Borchardt RT: VEGF increases BMEC monolayer permeability by affecting occludin expression and tight junction assembly. Am J Physiol Heart Circ Physiol 2001, 280:H434–440.PubMedGoogle Scholar
  28. Weis S, Cui J, Barnes L, Cheresh D: Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 2004, 167:223–229.View ArticlePubMedGoogle Scholar
  29. Weis S, Shintani S, Weber A, Kirchmair R, Wood M, Cravens A, McSharry H, Iwakura A, Yoon YS, Himes N, et al.: Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest 2004, 113:885–894.PubMedGoogle Scholar
  30. Ali N, Yoshizumi M, Fujita Y, Izawa Y, Kanematsu Y, Ishizawa K, Tsuchiya K, Yano S, Sone S, Tamaki T: A novel Src kinase inhibitor, M47 inhibits VEGF-induced human umbilical vein endothelial cell proliferation and migration. J Pharmacol Sci 5271, 98:130–141.View ArticleGoogle Scholar
  31. Furuse M, Itoh M, Hirase T, Nagafuchi A, Yonemura S, Tsukita S, Tsukita S: Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. J Cell Biol 1994, 127:1617–1626.View ArticlePubMedGoogle Scholar
  32. Mukhopadhyay D, Nagy JA, Manseau EJ, Dvorak HF: Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium. Cancer Res 1998, 58:1278–1284.PubMedGoogle Scholar
  33. Corada M, Mariotti M, Thurston G, Smith K, Kunkel R, Brockhaus M, Lampugnani MG, Martin-Padura I, Stoppacciaro A, Ruco L, et al.: Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci USA 1999, 96:9815–9820.View ArticlePubMedGoogle Scholar
  34. Esser S, Lampugnani MG, Corada M, Dejana E, Risau W: Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci 1998,111(Pt 13):1853–1865.PubMedGoogle Scholar
  35. Rabiet MJ, Plantier JL, Rival Y, Genoux Y, Lampugnani MG, Dejana E: Thrombin-induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization. Arterioscler Thromb Vasc Biol 1996, 16:488–496.PubMedGoogle Scholar
  36. Brinkkoetter PT, Beck GC, Gottmann U, Loesel R, Schnetzke U, Rudic B, Hanusch C, Rafat N, Liu Z, Weiss C, et al.: Hypothermia-induced loss of endothelial barrier function is restored after dopamine pretreatment: role of p42/p44 activation. Transplantation 2006, 82:534–542.View ArticlePubMedGoogle Scholar
  37. Katzung BG: Basic and clinical pharmacology. McGraw-Hill Publishing Co.; 2004.Google Scholar
  38. Bhattacharya R, Kang-Decker N, Hughes DA, Mukherjee P, Shah V, McNiven MA, Mukhopadhyay D: Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling. Faseb J 2005, 19:1692–1694.PubMedGoogle Scholar

Copyright

© Bhattacharya et al. 2008

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement